COMMUNIQUÉS West-GlobeNewswire

Prothena Discontinues Development of NEOD001 for AL Amyloidosis
23/04/2018
Phase 2b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor conference call and webcast today at 8:30 AM ET DUBLIN, [...]
Beacon Health Selects R1 RCM for Expanded Revenue Cycle Services
23/04/2018
CHICAGO, April 23, 2018 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM ), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced that Beacon Health based [...]
Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”
23/04/2018
SAN DIEGO, April 23, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, has been invited to participate as an expert panelist at the [...]
Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations
23/04/2018
SOUTH SAN FRANCISCO, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM ) today announced the appointment of Brad Kreger as Senior Vice President, Global Operations. In this role, Kreger leads [...]
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
23/04/2018
NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT ), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial [...]
Fulgent Genetics to Announce First Quarter 2018 Financial Results on Monday May 7, 2018
23/04/2018
TEMPLE CITY, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT ) (“Fulgent Genetics” or the “company”) today announced that it will release its first quarter 2018 financial results after [...]
Lotus Ventures Gets Confirmation of Readiness From Health Canada
23/04/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Health Canada License Update VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- Lotus Ventures Inc. (“Lotus” or the “ [...]
Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting
23/04/2018
SOUTH SAN FRANCISCO, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]
San Antonio Endovascular & Heart Institute First to Deploy Biotricity’s New Bioflux Remote Monitoring Device
23/04/2018
Biotricity Achieves Commercial Milestone Ahead of Schedule with First Customer REDWOOD CITY, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare [...]
Spectral Medical Completes $5.3 Million Financing
23/04/2018
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT ), a Phase III company developing the first treatment for patients with septic shock guided by a companion [...]
Tabula Rasa Healthcare’s SinfoníaRx Publishes Annual Performance Report
23/04/2018
Mission to improve lives of patients with chronic and complex illnesses continued in 2017 MOORESTOWN, N.J., April 23, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC ), a healthcare technology [...]
Precipio Completes a $3M Convertible Debt Facility
23/04/2018
Management focuses on growth opportunities NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO ), announced today that it entered into a convertible debt [...]
Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS’ The Aesthetic Meeting
23/04/2018
Four Presentations to Discuss the State of the Neurotoxin Industry IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS ) (“Evolus”), a lifestyle aesthetics company focused on delivering [...]
Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
23/04/2018
Company on track to file marketing authorization applications in the European Union in the second half of 2018 Data on utility in geographic regions also presented MADRID, Spain, April 23, 2018 (GLOBE NEWSWIRE) -- [...]
Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections
23/04/2018
- First presentation of the OASIS-2 topline results - Sub-analysis examining efficacy of oral-only omadacycline on lesion size also presented at ECCMID 2018 MADRID, Spain, April 23, 2018 (GLOBE NEWSWIRE) -- Paratek [...]
Misonix to Present at the 43rd Annual Deutsche Bank Health Care Conference on May 8
23/04/2018
FARMINGDALE, N.Y., April 23, 2018 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON ) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, [...]
Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018
23/04/2018
NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT ), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial [...]
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
23/04/2018
HALIFAX, Nova Scotia, April 23, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors will present an update [...]
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
23/04/2018
Geneva, Switzerland and Boston, MA - 23 April 2018 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that [...]

Pages